• Rosa Ana García Pliego, José Miguel Baena Díez, Yolanda Herreros Herreros, and Miguel Ángel Acosta Benito.
• Medicina de Familia, Centro de Salud Dr. Aguilar, Cubas de la Sagra, Madrid, España; Grupo de Atención al Mayor de la Sociedad Madrileña de Medicina Familiar y Comunitaria, Madrid, España; Grupo del Mayor del PAPPS de la Sociedad Española de Medicina Familiar y Comunitaria, España. Electronic address: draroux@yahoo.es.
• Aten Primaria. 2022 Aug 1; 54 (8): 102367.

AbstractThe use of drugs has undeniable benefits to the elderly, but it is not exempt from undesirable effects. Deprescription is the process of systematic medication review with the target of achieving the best risk-benefit ratio based on the best available evidence. This process is especially important for polymedicated elderly patients as well as those overtreated, frail, terminally ill and at the end of life. The deprescription must be done in stages, establishing a close follow-up in case problems appear after withdrawal. In the decision-making process, it is very important to consider the patient and caregivers opinion, assessing the objectives of the treatment according to the clinical, functional and social situation of the patient. There are multiple tools to make it easier for clinicians to select which drugs to deprescribe (Beers criteria, STOPP-START…). The most susceptible to intervention pharmacological groups are: antihypertensives, antidiabetics, statins, benzodiazepines, antidepressants, anticholinergics, anticholinesterase agents, and neuroleptics.Copyright © 2022 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.

15 keywords...

hide…